Re: Farmas USA
ALPMY
Creo que solo la llevo yo. Entrada a largo plazo como os dije que va viento en popa.
Amgen's Blincyto OK'd in Japan for ALL
The Japanese Ministry of Health, Labor and Welfare approves Amgen's (NASDAQ:AMGN) BLINCYTO (blinatumomab) for the treatment of patients with relapsed/refractory B-cell lymphoblastic leukemia (ALL).
BLINCYTO was developed there through a joint venture between Amgen and Astellas Pharma (OTCPK:ALPMF)(OTCPK:ALPMY) called Amgen Astellas BioPharma K.K.
«Después de nada, o después de todo/ supe que todo no era más que nada.»